Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Volunteers aiding humpback whale stranded in Baltic get death threats - 2Historical mysteries solved by science in 2025
- 3San Francisco sues 10 companies that make ultraprocessed food
- 4‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- 5Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Fears of global aluminum shortages intensify
- Iranian strikes on Israel injure 11 and set chemical plant ablaze
- Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- Mummified cheetahs found in Saudi caves shed light on lost populations
- Web designers for Independent ventures
